
    
      This is an open label, dose escalation study. Cohort of 3~6 patients receive escalation doses
      of CKD-516 until the maximum tolerated dose(MTD) is determined. The MTD is defined as the
      dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicity.
    
  